Quantcast
Last updated on April 23, 2014 at 10:50 EDT

Latest Aprepitant Stories

2014-02-11 20:21:26

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/tgtpbg/drug_solubility) has announced the addition of the "Concise Analysis of Drug Solubility Technology: Spray Drying, Extrusion, and SCF" [http://www.researchandmarkets.com/research/tgtpbg/drug_solubility ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) As drug suppliers re-examine their business models to adjust...

2014-01-29 16:29:05

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bgdzzw/tesaros) has announced the addition of the "Tesaro's Rolapitant: Competition for Emend" [http://www.researchandmarkets.com/research/bgdzzw/tesaros ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Tesaro's rolapitant is a NK-1 inhibitor in phase III trials for the prophylaxis of chemotherapy-induced nausea and...

2013-10-30 04:21:57

CAMBRIDGE, England, October 30, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications. CINV occurs in approximately...

2012-11-28 08:25:03

ALBANY, New York, November 28, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018 [http://www.transparencymarketresearch.com/cinv-market.html ]," the global CINV market was worth USD 1.3 billion in 2011 and is expected to...

2012-10-24 07:31:41

ALBANY, New York, October 24, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Netupitant - Palonosetron FDC - Global Market Opportunity Assessment Study, 2012 - 2018 [http://www.transparencymarketresearch.com/netupitant-palonosetron-fdc-market.html ]", the global Netupitant - Palonosetron FDC sales are expected to reach USD 515.0 million by 2018. The global Chemotherapy-induced nausea...

2011-06-08 05:00:00

LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48...

2010-10-13 07:00:00

NEW YORK and WHITEHOUSE STATION, N.J., Oct. 13 /PRNewswire-FirstCall/ -- Weight Watchers International, Inc., the world's leading provider of weight management services, and Merck, a global healthcare leader, announced today an innovative collaboration focused on fighting obesity. The two companies will launch an initiative in which Merck will provide physicians and other health care providers with educational information about the Weight Watchers® program and its...

2010-09-07 08:53:00

RYE, N.Y., Sept. 7 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development. In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products. As Curemark continues to anticipate expansion of its clinical trials...

2010-07-02 16:23:00

WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication. The FDA...

2010-06-11 09:09:00

Nausea and Vomiting Present Obstacles to Patients' Life-Saving Chemotherapy Maintenance; CareLine Program Provides Direct Assistance to Patients Experiencing Side Effects of Chemotherapy, Seeking Access to Anti-Nausea Care WASHINGTON, June 11 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) - a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial...